Cargando…

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus

The sequence of non-structural protein NS1 of bluetongue virus (BTV), which contains immunodominant CD8+ T cell epitopes, is highly conserved among BTV serotypes, and has therefore become a major tool in the development of a universal BTV vaccine. In this work, we have engineered multiserotype BTV v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Utrilla-Trigo, Sergio, Jiménez-Cabello, Luis, Alonso-Ravelo, Ruymán, Calvo-Pinilla, Eva, Marín-López, Alejandro, Moreno, Sandra, Lorenzo, Gema, Benavides, Julio, Gilbert, Sarah, Nogales, Aitor, Ortego, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564706/ https://www.ncbi.nlm.nih.gov/pubmed/32610561 http://dx.doi.org/10.3390/vaccines8030346

Ejemplares similares

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2(1-180)) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
por: Utrilla-Trigo, Sergio, et al.
Publicado: (2022)

Viral Vector Vaccines against Bluetongue Virus
por: Jiménez-Cabello, Luis, et al.
Publicado: (2020)

A protective bivalent vaccine against Rift Valley fever and bluetongue
por: Calvo-Pinilla, Eva, et al.
Publicado: (2020)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

Inhibition of Orbivirus Replication by Aurintricarboxylic Acid
por: Alonso, Celia, et al.
Publicado: (2020)

Natural Selection of H5N1 Avian Influenza A Viruses with Increased PA-X and NS1 Shutoff Activity
por: Nogales, Aitor, et al.
Publicado: (2021)

Epizootic Hemorrhagic Disease Virus: Current Knowledge and Emerging Perspectives
por: Jiménez-Cabello, Luis, et al.
Publicado: (2023)

CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR(−/−) Mice
por: Marín-López, Alejandro, et al.
Publicado: (2018)

Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
por: Marín-Lopez, Alejandro, et al.
Publicado: (2019)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
por: Lorenzo, María M., et al.
Publicado: (2023)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines
por: Kandeel, Mahmoud, et al.
Publicado: (2023)

Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design
por: Calvo-Pinilla, Eva, et al.
Publicado: (2020)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus
por: Calvo-Pinilla, Eva, et al.
Publicado: (2012)

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
por: Kang, Chun-Min, et al.
Publicado: (2022)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
por: Alharbi, Naif Khalaf, et al.
Publicado: (2017)

Pathological Characterization Of IFNAR(-/-) Mice Infected With Bluetongue Virus Serotype 4
por: Marín-López, Alejandro, et al.
Publicado: (2016)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor
por: Calvo-Pinilla, Eva, et al.
Publicado: (2009)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

Bluetongue Virus Nonstructural Protein NS3/NS3a Is Not Essential for Virus Replication
por: van Gennip, René G. P., et al.
Publicado: (2014)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers
por: Verma, Alka, et al.
Publicado: (2022)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

Atomic structure of the translation regulatory protein NS1 of bluetongue virus
por: Kerviel, Adeline, et al.
Publicado: (2019)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h9r2bp6s9fs6dvq5ngflpppgub